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Background: The long-term survival in hepatocellullar carcinoma (HCC) patients after transarterial
chemoembolization (TACE) remains dismal due to local and/or regional recurrence as well as distant metastasis. The
efficacy of sorafenib in advanced HCC has been demonstrated and brought great hope. Recently, the use of
sorafenib in combination with TACE for BCLC stage B and C HCC patients was recommended. However, data on
this dual-modality treatment is little, and its advantage over TACE alone has not been addressed. The present study
sought to understand the efficacy of the combination of TACE and sorafenib in the treatment of advanced HCC.
Methods: Between June 2008 and Feb 2011, 45 patients with advanced HCC were enrolled and treated with
sorafenib in combination with TACE according to an institutional protocol of the Zhongshan hospital, Fudan
University. The control group of 45 other HCC patients with similar characteristics treated with TACE alone in the
same period of time in our institute were selected for retrospective comparison of the treatment outcomes
especially overall survival time. Adverse reactions induced by sorafenib were observed and recorded.
Results: The median overall survival time of the combined treatment group was 27 (95% Confidence Interval:
21.9–32.1) months, and that of TACE alone group was 17 months (95% Confidence Interval: 8.9–25.0) months
(P= 0.001). Patients required significantly less frequent TACE for their symptomatic treatment after the initiation
of sorafenib therapy. The most common adverse events associated with sorafenib were hand-foot skin reaction, rash
and diarrhea. Of CTCAE grade IV or V toxicity was observed.
Conclusion: TACE combined sorafenib significantly prolonged median overall survival time of patients with
advanced HCC.Background
Hepatocellular carcinoma (HCC) is one of the most
common and fatal gastrointestinal malignancies. The in-
cidence of HCC in China is particularly high, accounting
for 55% of all cases diagnosed worldwide [1,2]. The de-
finitive treatment modality for HCC is surgical resection.
However, complete resection is not feasible for the ma-
jority of patients because of advance disease when diag-
nosed [3-5]. Transarterial chemoembolization (TACE) is
generally accepted as an effectively palliative treatment
for patients with unresectable HCC. Despite of the effi-
cacy in local disease control and symptomatic relief,
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reproduction in any medium, provided the ordismal due to local and/or regional recurrence, as well
as distant metastasis [6-10]. Clearly, effectively systemic
treatment for advanced HCC is urgently needed.
Sorafenib is a multikinase inhibitor with effects on
tumor proliferation and angiogenesis [11]. The efficacy
of sorafenib in advanced HCC has been demonstrated
repeatedly in phase II and phase III randomized trials
[11,12]. In a recently published phase II clinical trial, the
use of sorafenib in combination with TACE for BCLC
stage B and C HCC patients was recommended. How-
ever, data on this dual-modality treatment is little, and
its advantage over TACE alone has not been addressed.
The aim of this report is to bolster the existing but lim-
ited data by documenting the outcome of patients with
advanced HCC treated with TACE and sorafenib. The
treatment outcomes of this group of patients were also
compared in a retrospective fashion with another group. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Methods
Between June 2008 and Feb 2011, 45 patients with
advanced stages of HCC (BCLC-B, C) were enrolled and
treated with sorafenib in combinatin with TACE(TACE+
sorafenib group) according to an institutional treatment
protocol at the Zhongshan hospital, Fudan University. All
patients were diagnosed by histology, cytology, or persist-
ently elevated serum alpha-fetoprotein (AFP≥ 400 ng/ml)
with typical imaging findings. Histological or cytological
confirmation for the diagnosis of HCC was mandatory for
patients with AFP< 400 ng/ml. Other inclusion criteria
for this protocol included (1) unresectable multinodular
asymptomatic HCC unsuitable for surgical resection
according to the Barcelona Clinical Liver Cancer (BCLC)
staging classification, and (2) Child-Pugh class A and B
without encephalopathy with ECOG Performance Status
of 0-1. An additional group of 45 HCC patients with simi-
lar characteristics including age, gender, BCLC stage of
the disease, Child-Pugh classification, and ECOG per-
formance status were selected and matched at 1:1 ratio for
a retrospective comparison of the treatment outcome.
Treatment
Transarterial chemoembolization
Angiography of celiac, hepatic, superior mesenteric, left
gastric, and inferior phrenic arteries was performed to
identify all feeding arteries of the tumor. A 2.7–5.0 F
catheter was then inserted into the target artery. Oxali-
platin (100–200 mg) and/or fluorouracil glycosides
(500–1000 mg) were infused followed by epirubicin
(30–60 mg) mixed with 5–25 ml of iodized oil under
fluoroscopic monitoring. The mixture was infused at a
rate of 0.5–1 ml/min until stasis flow in tumor vascular-
ity was achieved. Finally, gelatin sponge or 300–500um
micosphere was used to embolize the feeding artery of
tumor.
Sorafenib treatment
Patients who were treated with sorafenib were pre-
scribed with two tablets of sorafenib (200 mg tablet)
twice daily. The recommended dose adjustment that
reduced the dose to the lowest level according to
CTCAE would be used. When the drug-related adverse
events panished, whether taking sorafenib 400 mg twice
daily were decided according to the different types of the
adverse events by clinical doctors.
Follow-up
All patients treated in our center for HCC were required
to be followed up according to our institutional protocol.
Each follow-up session includes a detailed history andphysical examination, ECOG performance status classifi-
cation, Child pugh score evaluation, and an abdominal
enhanced CT/MRI scan. All patients were followed up
at a 6- to 8-week interval.
Statistical analysis
The primary objective of the current study was overall
survival (OS), which refers to the time between first
TACE to death by any cause. The treatment outcomes
of the HCC TACE group were compared with the TACE
combined with sorafenib group. Survival analysis was
estimated by the Kaplan-Meier survival method and
compared by the log-rank test. All statistical tests were
two-sided, P< 0.05 was considered statistically signifi-
cant. Statistical analysis was performed with Statistical
Product and Service Solutions computer software for
Windows (SPSS Inc, Chicago, IL).
Results
Characteristics of patients and disease
The characteristics of patients and their diseases includ-
ing age, gender, stage, Child-Pugh classification, AFP
level prior to treatment, tumor type and size, prior his-
tory of hepatitis, liver function, as well as the presence
of PVT and/or metastasis are listed in Table 1. There is
no significant difference in any of the characteristics be-
tween the two groups of patients.
Survival
The median survival time of the combined treatment
group was 27 (95% Confidence Interval 21.9–32.1)
months and that of TACE alone group was 17 (95%
Confidence Interval 8.9–25.0) months (P= 0.001)
(Figure 1).
The median survival time of patients with portal vein
thrombosis and/or distant metastasis was shorter than
those who had neither (Table 2). The addition of sorafe-
nib significantly improved the overall survival of both
group of patients. Furthermore, when sorafenib was
added to TACE, the significance of portal vein thromo-
bosis/metastasis on overall survival diminished (27.2 vs.
29.1 months, P= 0.558) (Figure 2).
Adverse effects (adverse events related to sorafenib)
No grade IV or V toxicity occurred in either group of
patients. Table 3 details the incidence of all grade 1–3
(CTCAE v. 3.0) toxicities secondary to sorafenib
observed based on the Common Terminology Criteria
for Adverse Events (CTCAE) version 3.0. Commonly
observed adverse effects in our group of patients
received sorafenib included fatigue, skin reaction, hear
loss, nausea/anorexia, diarrhea, hypertension, depres-
sion, and muscle ache.
Table 1 The basic demographic and disease
characteristics
TACE+ Sorafenib TACE P
(n=45) (n=45)
Age 51± 11.7 49 ± 11.0 >0.05
Men/women 41/4 41/4 >0.05
PVT 20 23 >0.05
Distant metastasis 11 12 >0.05









<400 ng/ml 16 19
≥400 ng/ml 29 26




















TACE: transcatheter arterial chemoembolization; TACE-S: TACE combined with
sorafenib; BCLC: Barcelona Clinic Liver Cancer; ECOG PS: Eastern Cooperative
Oncology Group Performance Status; HBV, hepatitis B virus; HCV, hepatitis C
virus; AFP, alpha-fetoprotein, AST, aspartate aminotransferase.
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vomiting, tenderness in the right upper abdomen, fever,
and transient LFT dysfunction. However, no grade 4 or
above TACE-induced adverse-effect was observed.TACE was administrated in each group of patients,
and in the group of combination therapy sorafenib was
initiated after at least one TACE procedure. The dur-
ation time of taking sorafenib is 11.61 ± 5.3 months. All
patients in both treatment groups experienced all grades
of adverse events induced by TACE, of which some
patients experienced grade 3 adverse events based on
CTCAE 3 and return to CTCAE grade 1 after proper
treatment. Grade 4 or above adverse events was not
observed in both groups. In consideration of the possible
overlaying of adverse events induced by TACE and sora-
fenib, sorafenib was interrupted for 3 days prior to
TACE and at least 3 days after TACE during the com-
bination therapy, and return to dosing when liver func-
tions, the blood test and embolism syndrome CTCAE
assessment reached CTCAE grade 1 or lower.
Discussion
Patients’ outcomes with TACE have been recently
improved based on the application of micro-catheter
technique and doxorubicin-eluting beads technique. The
survival benefits of TACE were better in patients with
focal liver lesions, hypervascular tumors and without
vascular invasion [4]. TACE was usually not performed
in the case of multiple lesions, hypovascular tumor, and
vascular invasion even extra-hepatic disease. The limita-
tion of TACE was the incomplete target lesion necrosis,
which made patients require repeated TACE treatments.
In addition, residue tumor proliferation, tumor recur-
rence and metastasis after TACE influenced long-term
outcome [13,14]. Comprehensive therapy based on com-
bination with systemic therapy played an important role
in improving the efficacy of therapy for advanced HCC.
The development of molecular targeted agent sorafenib,
one of systemic therapies, brought hope for HCC
patients.
Sorafenib, an orally active multikinase inhibitor with
effects on tumor-cell proliferation and tumor angiogen-
esis, was initially identified as a Raf kinase inhibitor, by
inhibiting the serine-threonine kinase Raf-1 and B-Raf.
It also inhibits vascular endothelial growth factor recep-
tors (VEGFR) 1, 2, and 3; platelet-derived growth factor
receptor β(PDGFR); and RET receptor tyrosine kinases.
Sorafenib inhibits MEK and ERK phosphorylation,
down-regulates cyeline D1 level, reduces eIF4E phos-
phorylation and down-regulates anti-apoptosis protein
Mc11 [15,16]. In SHARP and Oriental trials, monother-
apy with sorafenib significantly prolonged overall survi-
vals (44% and 47% respectively) and delayed time to
progression (73% and nearly 1 fold respectively) in
patients with advanced HCC compared with that in pla-
cebo recipients. Moreover, treatment with sorafenib was
well tolerated and safe. Based on these data, sorafenib
was recommended as the standard treatment for
Figure 1 Kaplan-Meier overall survival functions for TACE+ sorafenib group and TACE group.
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the efficacy of monotherapy with sorafenib was limited
since the absolute benefit in survival time compared
with placebo was not so prominent.
In view of liver primary lesion, portal vein invasion
and distant metastasis, there has been a consensus on
comprehensive therapy based on combination therapy
for intermediate-advanced HCC. The efficacy of the
combining use of sorafenib and TACE in patients with
advanced HCC including those with BCLC stage C dis-
ease was suggested in a recently published phase II clin-
ical trial [17]. Close to 60% of patients achieved
objective response and the treatment was well tolerated
although 40 sorafenib dose interruptions were observed.
However, patients’ survival has not been reported.Table 2 Comparison of the median survival time of
patients with or without portal vein thrombosis and/or
distant metastasis
Groups n Mean (95%
Confidence Interval)
P value
HCC without portal vein
thrombosis/metastasis




HCC with portal vein
thrombosis/metastasis
TACE 23 12.00 (9.96–16.02) 0.041
TACE +
Sorafenib
20 27.20 (19.07–35.32)The enrolled patients in our study were those of unre-
sectable HCC, BCLC stage B or C. Baseline characteris-
tics were well balanced between the study groups. The
median survival time in the group treated with sorafenib
plus TACE was 27 (95% Confidence Interval: 21.89–
32.10) months, while the median survival time in the
group of TACE alone was 17 (95% Confidence Interval:
12.66–29.33) months (Figure 1). Our data indicated that
sorafenib could prolong the median survival time of
patients with HCC treated with TACE.
We also observed that there was no significant differ-
ence in the median survival time between patients with
portal vein thrombosis and distant metastasis and those
without portal vein thrombosis and distant metastasis in
combination therapy group. Although there was prob-
ably certain statistics deviation due to the small sample
size, it is still suggested that sorafenib could cover the
shortage of TACE to improve the outcome of patients
with vascular invasion and distant metastasis.
Various adverse events occurred during sorafenib
treatment in clinical practice, and significant individual
differences were also found. However, no grade 4 ad-
verse events were observed and the most common grade
3 events were hand-foot skin reactions and hyperten-
sion. Patients received full guidance during the treat-
ment, thus adverse events were relieved after additional
prevention, treatment and dose adjustment of sorafenib.
Discontinuation due to adverse events was not observed.
Figure 2 Kaplan-Meier overall survival functions for TACE+ sorafenib group and TACE group in patients with PVT and distant
metastasis and without PVT and distant metastasis separately..
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not increase sorafenib related adverse events.
Although patients received sorafenib +TACE were
accrued and treated according to our institutional proto-
col, the comparison between those with or without sora-
fenib therapy were retrospective in nature. Therefore,
during the selection of patients treated with TACE alone,
efforts were applied to avoid selection bias and the char-
acteristics of patients and their diseases matched well in
our two groups. Furthermore, as the survival data of
patients treated with sorafenib in combination with
TACE were not available at the time of our study design,
sample size calculation for a phase II clinical trial was
not possible. We consider retrospective nature of the
comparison as well as a small sample size of 45 patients
two substantial limitations of the current study.Table 3 The adverse events after intaking of sorafenib
[the number of cases (%)]
CTCAE grade I II III
Symptom Number (%) Number (%) Number (%)
Hand-foot skin reaction 10 (22.2) 15 (33.3) 12 (26.7)
Rash 19 (42.2) 5 (11.1) 2 (4.44)
Diarrhea 17 (37.8) 4 (8.89) 1 (2.22)
Hair loss 17 (37.8) 2 (4.44) 2 (4.44)
Hypertension 15 (33.3) 7 (15.6) 3 (6.67)
Fatigue 22 (48.9) 3 (6.67) 0 (0)
Anorexia 12 (26.7) 2 (4.44) 0 (0)
Nausea 11 (24.4) 1 (2.22) 0 (0)
Depression 9 (20) 0 (0) 0 (0)
Muscle aches 14 (31.1) 0 (0) 0 (0)The results of our current study and the above-
mentioned phase II trial provided the only documentation
of the efficacy and safety of the combination of sorafenib
and local treatment using TACE. Clearly, these results
are far from conclusive. The survival advantage of the
combination of sorafenib and TACE over sorafenib alone
has never been addressed. Furthermore, the optimal use
of this combination, especially the optimal timing of
TACE during sorafenib use needs to be studied. A num-
ber of recently published trials indicated that the use of
external beam radiotherapy or I-125 implant might fur-
ther improve local control of the intrahepatic disease
[18,19]. Whether the combination of sorafenib with
TACE and/or radiotherapy can further improve patients’
survival also needs further investigation.Conclusion
The combination of sorafenib and TACE produced a
median survival time of 27 months in patients with
advanced HCC, significantly longer than 17 months of
patients treated with TACE alone. Sorafenib also
reduced the frequency of TACE required for intrahepa-
tic symptomatic control. The combination of sorafenib
and TACE was well tolerated with no severe adverse
events observed in our group of patients. Further stud-
ies preferably in a randomized fashion are required to
compare the efficacy of the combination of sorafenib and
TACE to either sorafenib or TACE, as well as the obser-
vation of the optimal sequence of such combination.Competing interests
The authors declare that they have no competing interests.
Qu et al. BMC Cancer 2012, 12:263 Page 6 of 6
http://www.biomedcentral.com/1471-2407/12/263Authors’ contributions
XD Q and CS C contributed to acquisition of data, analysis and interpretation
of data, performing the statistical analysis; JH W contributed to conception
and design, and drafting the manuscript; ZP Y helped to draft the
manuscript; JM C, GQ G, QX L, JJ L, LX L, R L; S Q contribute to Collection of
cases. All authors read and approved the final manuscript.
Received: 9 December 2011 Accepted: 21 June 2012
Published: 21 June 2012References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Globle cancer statistics, 2002. CA
Cancer J Clin 2005, 55(1):74–108.
2. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003,
362:1907–1917.
3. Arii S, Yamaoka Y, Futagawa S, et al: Results of surgical and nonsurgical
treatment for small-sized hepatocellular carcinomas: a retrospective and
nationwide survey in Japan. Hepatology 2000, 32:1224–1229.
4. Llovet JM, Bruix J: Systematic review of randomized trials for
unresectable hepatocellular carcinoma: chemoembolization improves
survival. Hepatology 2003, 37:429–442.
5. Ikai I, Arii S, Kojiro M, et al: Reevaluation of prognostic factors for survival
after liver resection in patients with hepatocellularcarcinoma in a
Japanese nationwide survey. Cancer 2004, 101:796–802.
6. Lo CM, Ngan H, Tso WK, Wong J, et al: Randomized controlled trial of
transarterial Lipiodol chemoembolization for unresectable hepatocellular
carcinoma. Hepatology 2002, 35:1164–1171.
7. Dong-Jun Yoo, Kang Mo Kim, Young-Joo Jin, et al: Clinical outcome of 251
patients with extra hepatic metastasis at initial diagnosis of
hepatocellular carcinoma: Does transarterial chemoembolization
improve survival inthese patients? J Gastroenterol Hepatol 2011,
26:145–154.
8. Llovet JM, Real MI, Montana X, et al: embolization or chemoembolization
versus symptomatic treatment in patients with unresectable
hepatocellular carcinoma: a randomized controlled trial. Lancet 2002,
359:1734–1739.
9. Llovet JM, et al: Arterial embolization or chemoembolization versus
symptomatic treatment in patients with unresectable hepatocellular
carcinoma: a randomised controlled trial. Lancet 2002, 359:1734–1739.
10. Liapi E, Geschwind JF: Transcatheter Arterial Chemoembolization for Liver
Cancer: Is It Time to Distinguish Conventional from drug-Eluting
Chemoembolization? Cardiovasc Intervent Radiol 2011, 34(1):37–49.
11. Llovet J, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular
carcinoma [J]. N Engl J Med 2008, 359(4):378–390.
12. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in
patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: A phase III randomized, double blind, placebo controlled trial
[J]. Lancet Oncol 2009, 10(1):25–34.
13. Esther A, Carlos V, Juan D, et al: Transcatheter Arterial Chemoembolization
in Patients with Hepatocellular Carcinoma on the Waiting List for
Orthotopic Liver Transplantation. Am J Roentgenol 2008, 190:1341–1348.
14. Livraghi T, Mäkisalo H: P.-D. Line3. Treatment options in hepatocellular
carcinoma today. Scand J Surg 2011, 100:22–29.
15. Keating GM, Santoro A: Sorafenib: a review of its use in advanced
hepatocellular carcinoma. Drugs 2009, 69(2):223–240.
16. Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein
kinase cascade for the treatment of cancer. Oncogene 2007,
26:3291–3310.
17. Pawlik-Timothy M, Reyes-Diane K, David-Cosgrove, et al: Phase II Trial of
Sorafenib Combined With Concurrent Transarterial Chemoembolization
With Drug-Eluting Beads for Hepatocellular Carcinoma, Journal of clinical
oncology. J Clin Oncol 2011, 9:3960–3967.
18. Luo J, Yan Z, Liu Q, Qu X, Wang J: Endovascular placement of iodine-125
seed strand and stent combined with chemoembolization for treatment
of hepatocellular carcinoma with tumor thrombus in main portal vein.
Journal of Vascular and Interventional Radiology 2011, 22(4):479–489.
19. Zhang XB, Wang JH, Yan ZP, Qian S, Liu R: Hepatocellular carcinoma
invading the main portal vein: treatment with transcatheter arterial
chemoembolization and portal vein stenting. Cardiovasc Intervent Radiol
2009, 32:52–61.doi:10.1186/1471-2407-12-263
Cite this article as: Qu et al.: The efficacy of TACE combined sorafenib in
advanced stages hepatocellullar carcinoma. BMC Cancer 2012 12:263.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
